Jennifer Cohen, PhD, DABT

Sr. Scientific Director- Early Immunology Therapeutic Area Lead, NCS Portfolio Scientific Leadership @ Johnson & Johnson

About

Pharmaceutical Toxicologist (board certified, DABT) with 15+ years of industry experience in development of small molecules, antibodies, antisense oligonucleotides, and cell therapy across CNS, GI, metabolic, immunology, and oncology therapeutic areas. Regulatory toxicology experience authoring IND/BLA/NDA in global regions, including FDA/EMA/HC/CDE/PMDA/etc. Supports all stages of drug discovery, development, and marketed drugs and expansion of indications. Experience as lead toxicologist and cross functional program team leader on both internal teams and joint project teams with partner companies. Open to Board of Director opportunities.

Country

United States

City

San Diego

Industry

Pharmaceuticals

Skill

Small Molecules, Lipid nanoparticles, Gastroenterology, Stem Cell Therapy, Antisense oligonucleotides, Safety biomarkers, Regulatory toxicology, Neuroscience, In Vitro, Cell Based Assays, In Vivo, Cancer, Pharmacology, Assay Development, Protein Chemistry, Stem Cells, Confocal Microscopy, Cell, Toxicology, Drug Development

Experience

Sr. Scientific Director- Early Immunology Therapeutic Area Lead, NCS Portfolio Scientific Leadership

Johnson & Johnson

2025-4 - Present · 1 yr 6 mos

San Diego, California, United States

Toxicology Director/Group Leader

Takeda

2011-10 - 2024-10 · 13 yrs 1 mo

San Diego, California, United States

-Manager / People Leader - Serves on Global Leadership Team (LT) of Toxicology Project Support and on San Diego Site LT. - Organizational leader and scientific driver for nonclinical research strategy. - Authored nonclinical modules of numerous INDs/CTAs and NDA/BLA (Alofisel). - Provided safety evaluation of 15+ in-licensing opportunities and out-Licensing of assets. - Leadership of multiple Global Working Groups and Strategy Teams. - Led global team to develop neurotoxicity screening assays incorporated into discovery screening paradigm

Investigative Toxicology

Roche

2009-11 - 2011-10 · 2 yrs

Nutley, New Jersey, United States

• Initiated hypothesis driven research to determine mechanism of small molecule anticancer inhibitors in cardiotoxicity; utilizing human stem cell derived cardiomyocytes. • Contributed to development of an impedance assay to estimate drug-induced proarrhythmic risk in human stem cell derived cardiomyocytes. • Developed a quantitative 96-well HTS and completed a small molecule library screen to identify compounds that pushed the differentiation of human embryonic stem cells and to functionally contracting cardiomyocytes. • Increased knowledge of cardiomyocyte electrophysiology, kinase signaling, and differentiation. • Validated use of human embryonic stem cell and human induced pluripotent stem cell derived cardiomyocytes as a toxicology tool.

PhD, Pharmacology and Toxicology

University of Arizona

2004-8 - 2009-11 · 5 yrs 4 mos

• Conducted in vivo bioassay for renal tumor xenografts in athymic nude mice and in the Eker rat (Tsc-2EK/+) to study kinase signaling in tuberous sclerosis renal cell carcinoma (RCC) • Elucidated kinases involved in renal cancer in in vitro renal cell carcinoma model, quinol transformed primary renal epithelial cells derived from Tsc-2EK/+ rats (QTRRE cells) • Performed kinase assays, renal toxicity assays, and confocal microscopy to confirm modulation of signaling pathways in RCC • Contributed to renal and prostate cancer signal transduction pathways • Used mass spectrometer MALDI-TOF analysis to identify post-translational modifications to key proteins during chemically induced renal cell carcinoma